Everest Organics Limited

EVERESTO6

INE334C01029

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:12:01 2024-05-31 EDT			5-day change	1st Jan Change
122.4 ^INR	-0.16%		-4.52%	-3.32%

05-27	Everest Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI
02-09	Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Everest Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2021

August 05, 2021 at 07:55 am

Everest Organics Limited announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 514.577 million compared to INR 433.847 million a year ago. Net income was INR 21.329 million compared to INR 35.79 million a year ago. Basic earnings per share was INR 2.67 compared to INR 4.47 a year ago.

Latest news about Everest Organics Limited

Everest Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-27	CI
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-09	CI
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-09	CI
Everest Organics Limited Appoints Abdur Rahman as Company Secretary and Compliance Officer	11-11	CI
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-11	CI
Everest Organics Limited Announces Resignation of Rekha Singh as Company Secretary and Compliance Officer	23-10-09	CI
Everest Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-12	CI
Everest Organics Limited Announces the Demise of Sree Rama Krishna Grandhi, Non-Executive Independent Director	23-08-01	CI
Everest Organics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-27	CI
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-11	CI
Everest Organics Limited Declares Dividend for the Financial Year Ended March 31, 2022	22-09-26	CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to B+; Raises Outlook to Stabe	22-08-23	MT
Everest Organics Names New Managing Director; Shares Climb 3%	22-08-09	MT
Everest Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-09	CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to BB; Outlook Lowered to Negative	22-06-09	MT
Everest Organics Limited Announces the Demise of Dr. Srikakarlapudi Srihari Raju, Managing Director	22-05-27	CI
Everest Organics Limited Recommends Dividend for the Financial Year 2021-22	22-05-27	CI
Everest Organics Managing Director Passes Away	22-04-27	MT
Everest Organics Limited Announces Demise of Dr. Srikakarlapudi Srihari Raju, Managing Director of the Company	22-04-27	CI
ICRA Cuts Rating on Everest Organics' Term Loan, Cash Credit to BB+; Outlook Stable	22-03-02	MT
Everest Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-11	CI
Everest Organics Gets Permanent Revocation of Factory Closure Order	22-02-09	MT
Everest Organics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-13	CI
Everest Organics : Develops Active Pharmaceutical Ingreditent to Treat COVID-I9	21-10-12	MT

Chart Everest Organics Limited

Duration

Period

More charts

Company Profile

Everest Organics Limited is engaged in manufacturing of active pharmaceutical ingredients (API) and their intermediaries. It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen, Benzimadizole. The Companyâs APIâs products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5- Thiazolecarboxylate, Ethyl 2-(3-Formyl -4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl -4-Isobutoxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Cyano -4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, and 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
EVEREST ORGANICS LIMITED	-3.32%	11.74M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B